Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CD200 expression marks leukemia stem cell (LSC) in human AML part 1

ABSTRACT: CD200 expression marks leukemia stem cell (LSC) in human AML part 1

PROVIDER: PRJNA668360 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12802772_1.fastq.gz	Fastqsanger.gz
	SRR12802772_2.fastq.gz	Fastqsanger.gz
	SRR12802773_1.fastq.gz	Fastqsanger.gz
	SRR12802773_2.fastq.gz	Fastqsanger.gz
	SRR12802774_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

CD200 expression marks leukemia stem cell (LSC) in human AML part 3

Project description:The leukemia stem cell (LSC) populations of acute myeloid leukemia (AML) exhibit phenotypic, genetic and functional heterogeneity that contribute to therapy failure and relapse. Progress towards understanding the mechanistic basis for therapy resistance in LSCs has been hampered by difficulties in isolating cell fractions that enrich for the entire heterogeneous population of LSCs within individual AML samples. We previously reported that CD200 gene expression is upregulated in LSC-containing AML fractions. We demonstrate that CD200 is present on a greater proportion of CD45dim blasts compared to more differentiated CD45high cells in AML patient samples. In 75% of AML cases examined, CD200 was expressed on 10% of CD45dim blasts; of these, CD200 identified LSCs within the blast population in 90% of samples tested in xenotransplantation assays. Notably, CD200 expression captured both CD34- and CD34- LSCs within individual AML samples. Highly purified CD45dimCD200+ LSC-containing blasts were enriched in primitive HSC/progenitor-like signatures, while CD45dimCD200- nonengrafting blasts were enriched in myeloid-like signature. Moreover, analysis of CD45dimCD200+ blasts from NPM1-mutated AMLs also demonstrated an enrichment of primitive gene expression signatures compared to unfractionated (bulk) cells.

2020-10-10 | GSE159322 | GEO

CD200 expression marks leukemia stem cells (LSC) in human AML part 2

2020-10-10 | GSE159321 | GEO

CD200 expression marks leukemia stem cell (LSC) in human AML part 1

2020-10-10 | GSE159319 | GEO

CD200 expression marks leukemia stem cell (LSC) in human AML part 3

Project description:CD200 expression marks leukemia stem cell (LSC) in human AML part 3

| PRJNA668362 | ENA

CD200 expression marks leukemia stem cells (LSC) in human AML part 2

Project description:CD200 expression marks leukemia stem cells (LSC) in human AML part 2

| PRJNA668363 | ENA

CD200 expression marks leukemia stem cell (LSC) in human AML

Project description:CD200 expression marks leukemia stem cell (LSC) in human AML

| PRJNA668358 | ENA

RNA-seq of LSC-like, non-LSC and Mature populations from human AML patient samples

Project description:Acute myeloid leukemia (AML) is a highly heterogeneous disease and reliable detection of leukemic stem cells (LSCs) across genetic subclasses has proven difficult. We aimed to transcriptionally characterize LSCs specifically in monocyte-like AML (Mono-AML) and and primitive-like AML (Prim-AML) samples using cell surface markers. We used CD64+CD11b+ to define Mature blasts and labelled the rest as Immature. To further enrich for LSC-like cells in the Immature blasts in both Mono- and Prim-AML samples, we included GPR56, a marker for LSCs. We performed RNA sequencing on the FACS-sorted LSC-like and Mature cells from 23 AML patients.

2023-03-01 | E-MTAB-11976 | biostudies-arrayexpress

CD200 expression marks leukemia stem cell (LSC) in human AML

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-10-10 | GSE159323 | GEO

T cell response to CD200+/- acute myeloid leukemia

Project description:Purpose: Understanding immunosuppression in AML is critical . The goals of this study are to compare the transcriptomics of human CD3+ T cells from humanized mice exposed to CD200+/- AML. Methods: NSG mice were humanized with 10x10^6 healthy PBMCs prior to the introduction of CD200+ or CD200- OCI-AML3 cells. After 10 days, CD3+ T cells were isolated and RNA was sequenced. Results: T cells from mice with CD200+ AML were characterized by an enrichment of T cell activation pathways and a downregulation of numerous metabolic pathways, including OXPHOS and glycolysis. Conclusions: Our results demonstrate, for the first time, that CD200+ AML can directly impair T cell metbolism.

2021-04-24 | GSE173194 | GEO

Leucegene: AML sequencing (part 6)

Project description:Leucegene: AML sequencing (part 6)

| PRJNA416098 | ENA